Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.59 |
| ▸ | RHOC | P08134 | 6/20 | 0.57 |
| ▸ | RHOA | P61586 | 6/20 | 0.57 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615458 | 0.90 | TACR1 (0.50) | TACR1RHOCRHOACES2EGLN1 | |
| SCHEMBL3898783 | 0.89 | KDM4E (0.53) | TACR1RHOCRHOACES2EGLN1 | |
| Hydrochloric Acid SCHEMBL6776606 | 0.88 | KDM4E (0.51) | TACR1RHOCRHOAEGLN1GAA | |
| SCHEMBL25421238 | 0.87 | TACR1 (0.48) | TACR1RHOCRHOACES2EGLN1 | |
| SCHEMBL22400334 | 0.87 | NOTUM (0.50) | TACR1RHOCRHOACES2EGLN1 | |
| SCHEMBL28429392 | 0.86 | TACR1 (0.47) | TACR1RHOCRHOACES2EGLN1 | |
| SCHEMBL22400302 | 0.85 | TACR1 (0.46) | TACR1RHOCRHOACES2EGLN1 | |
| SCHEMBL14529137 | 0.84 | GAA (0.57) | TACR1RHOCRHOACES2GAA | |
| SCHEMBL22400427 | 0.84 | NOTUM (0.50) | TACR1RHOCRHOAEGLN1KDM4E | |
| SCHEMBL25422743 | 0.84 | TACR1 (0.45) | TACR1RHOCRHOACES2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | PFIZER INC. | 2007-01-04 | — | — | US | claimed |
| EP-1670765-A2 | CETP INHIBITORS AND METABOLITES THEREOF | Pfizer Products Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| WO-2005033082-A2 | CETP INHIBITORS AND METABOLITES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-04-14 | — | — | WO | claimed |
| EP-2376475-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| US-8912341-B2 | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones | NORTHWESTERN UNIVERSITY (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2419419-B1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-03 | — | — | EP | disclosed |
| CN-102459227-B | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 | JANSSEN PHARMACEUTICA NV | 2014-08-20 | — | — | CN | disclosed |
| US-20140206886-A1 | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones | NORTHWESTERN UNIVERSITY (US) | 2014-07-24 | — | — | US | disclosed |
| US-8513229-B2 | 4-Azetidinyl-1-phenyl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-20 | — | — | US | disclosed |
| US-8450304-B2 | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-20120252792-A1 | METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-04 | — | — | US | disclosed |
| WO-2010121046-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010068663-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | PFIZER INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | PFIZER INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | PFIZER INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1670765-A2 | CETP INHIBITORS AND METABOLITES THEREOF | Pfizer Products Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005033082-A2 | CETP INHIBITORS AND METABOLITES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-4612185-A | Methods and compositions for enhancing magnetic resonance imaging | MALLINCKRODT, INC. (US) | 1986-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | CETP, LCAT, MTTP | TACR1 1028/4885RHOC 2483/4885RHOA 3587/4885 |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCRL2 | TACR1 104/4885RHOC 3379/4885RHOA 3786/4885 |
| US-20140206886-A1 | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones | NISCH, NIM1K, CDK18 | TACR1 3114/4885RHOC 3675/4885RHOA 4717/4885 |
| US-20120252792-A1 | METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION | RHOA, RHOC, ROCK1 | TACR1 4047/4885RHOC 2/4885RHOA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.